436 related articles for article (PubMed ID: 23063301)
1. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia.
Uchimura N; Kamijo A; Kuwahara H; Uchiyama M; Shimizu T; Chiba S; Inoue Y
Sleep Med; 2012 Dec; 13(10):1247-53. PubMed ID: 23063301
[TBL] [Abstract][Full Text] [Related]
2. A polysomnography study of eszopiclone in elderly patients with insomnia.
McCall WV; Erman M; Krystal AD; Rosenberg R; Scharf M; Zammit GK; Wessel T
Curr Med Res Opin; 2006 Sep; 22(9):1633-42. PubMed ID: 16968566
[TBL] [Abstract][Full Text] [Related]
3. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia.
Erman MK; Zammit G; Rubens R; Schaefer K; Wessel T; Amato D; Caron J; Walsh JK
J Clin Sleep Med; 2008 Jun; 4(3):229-34. PubMed ID: 18595435
[TBL] [Abstract][Full Text] [Related]
4. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone.
Boyle J; Trick L; Johnsen S; Roach J; Rubens R
Hum Psychopharmacol; 2008 Jul; 23(5):385-97. PubMed ID: 18350566
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia.
Roth T; Walsh JK; Krystal A; Wessel T; Roehrs TA
Sleep Med; 2005 Nov; 6(6):487-95. PubMed ID: 16230048
[TBL] [Abstract][Full Text] [Related]
6. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial.
Pollack MH; Hoge EA; Worthington JJ; Moshier SJ; Wechsler RS; Brandes M; Simon NM
J Clin Psychiatry; 2011 Jul; 72(7):892-7. PubMed ID: 21367352
[TBL] [Abstract][Full Text] [Related]
7. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
Najib J
Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
[TBL] [Abstract][Full Text] [Related]
8. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults.
Rosenberg R; Caron J; Roth T; Amato D
Sleep Med; 2005 Jan; 6(1):15-22. PubMed ID: 15680290
[TBL] [Abstract][Full Text] [Related]
9. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder.
Sangal RB; Blumer JL; Lankford DA; Grinnell TA; Huang H
Pediatrics; 2014 Oct; 134(4):e1095-103. PubMed ID: 25266438
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
11. A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg.
Krystal AD; Huang H; Zummo J; Grinnell T; Marshall RD
Sleep Med; 2012 Jun; 13(6):691-6. PubMed ID: 22465450
[TBL] [Abstract][Full Text] [Related]
12. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
[TBL] [Abstract][Full Text] [Related]
13. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial.
Joffe H; Petrillo L; Viguera A; Koukopoulos A; Silver-Heilman K; Farrell A; Yu G; Silver M; Cohen LS
Am J Obstet Gynecol; 2010 Feb; 202(2):171.e1-171.e11. PubMed ID: 20035910
[TBL] [Abstract][Full Text] [Related]
14. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
Soares CN; Joffe H; Rubens R; Caron J; Roth T; Cohen L
Obstet Gynecol; 2006 Dec; 108(6):1402-10. PubMed ID: 17138773
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta®) and its effect on total sleep time, headache frequency, and daytime functioning: A randomized, double-blind, placebo-controlled, parallel-group, pilot study.
Spierings EL; McAllister PJ; Bilchik TR
Cranio; 2015 Apr; 33(2):115-21. PubMed ID: 25323219
[TBL] [Abstract][Full Text] [Related]
16. The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients.
Walsh JK; Thacker S; Knowles LJ; Tasker T; Hunneyball IM
Sleep Med; 2009 Sep; 10(8):859-64. PubMed ID: 19345644
[TBL] [Abstract][Full Text] [Related]
17. Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness.
Walsh JK; Salkeld L; Knowles LJ; Tasker T; Hunneyball IM
Sleep Med; 2010 Jan; 11(1):23-30. PubMed ID: 19945340
[TBL] [Abstract][Full Text] [Related]
18. A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome.
Rosenberg R; Roach JM; Scharf M; Amato DA
Sleep Med; 2007 Aug; 8(5):464-70. PubMed ID: 17512799
[TBL] [Abstract][Full Text] [Related]
19. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.
Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T
Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406
[TBL] [Abstract][Full Text] [Related]
20. Eszopiclone versus zopiclone in the treatment of insomnia.
Pinto LR; Bittencourt LR; Treptow EC; Braga LR; Tufik S
Clinics (Sao Paulo); 2016 Jan; 71(1):5-9. PubMed ID: 26872077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]